Continuation or reintroduction of bevacizumab beyond progression to fi rst-line therapy in metastatic colorectal cancer : fi nal results of the randomized BEBYP trial
F. Loupakis,A. Falcone,L. Salvatore,L. Fornaro,V. Sa,C. Cremolini,C. Granetto,C. Boni,C. Barbara,G. Allegrini,na,S. Chiara,D. Amoroso,A. Bonetti,M. Schirripa,G. Masi,E. Fea,S. Cupini,L. Boni,L. Antonuzzo
Abstract:Society of Clinical Oncology Gastrointestinal Cancers Symposium (Abstr 284), Orlando , FL, 2010. 10. Yancik R, Wesley MN, Ries LA et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82: 2123–2134. 11. Hines RB, Chatla C, Bumpers HL et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol 2009; 27: 4339–4345. 12. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–2704. 13. de Gramont E, Van Cutsem E, Schmoll HJ et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225–1233. 14. Allegra CJ, Yothers G, O’Connell MJ et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27: 3385–3390. 15. Allegra CJ, Yothers G, O’Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11–16. 16. Edge S, Byrd DR, Compton CC et al. AJCC Cancer Staging Manual, 7th edition. New York: Springer 2010. 17. Schmoll HJ, Twelves C, Sun W et al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol 2014; 15: 1481–1492. 18. McCleary NJ, Meyerhardt JA, Green E et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600–2606. 19. Sanoff HK, Carpenter WR, Martin CF et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104: 211–227. 20. Sanoff HK, Carpenter WR, Stürmer T et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012; 30: 2624–2634. 21. Fried LP, Ferrucci L, Darer J et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59: 255–263. 22. André T, Quinaux E, Louvet C et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732–3738. 23. Renfro LA, Grothey A, Kerr DJ et al. Survival following stage II/III colon cancer (CC): accent-based comparison versus matched general population (MGP). J Clin Oncol 2014; 32: Abstr 3601.
Medicine